Top accelerator startups

14,448 startups · 29 programs

BioDelivera

Active · Programmable drug delivery precisely targets only diseased cells

7signal of 100 · rising 7
  • went through YCProgram · this site+4
  • team of 2Team size · YC's directory+2.5

A sum of public facts, not a judgement and not investment advice.

Also from F26

All of F26

About BioDelivera

BioDelivera has developed proprietary GCV™, a drug delivery platform designed to travel through the body and selectively target diseased cells while sparing healthy ones. GCVs can carry genetic medicines, DNA, RNA, small molecules, or combinations of these at the same time. BioDelivera has demonstrated efficacy in tumors, muscle, and brain and is expanding to additional tissues. The company’s mission is to enable cures for every patient, across every disease.

YC batch
F26 · Fall 2026
Status, per YC
Active
Category
Other
Team size
2
Location
San Francisco, CA, USA
Checked
6h ago

YC tags: Gene Therapy, Cell Therapy, Drug Delivery

Changes seen

Joined a programNov 9, 2026

Joined Y Combinator's Fall 2026 batch (F26).

BioDelivera in F26: 219 companies, 89% AI

BioDelivera: questions

Which YC batch was BioDelivera in?

BioDelivera was in Y Combinator's Fall 2026 batch (F26).

Is BioDelivera still active?

Y Combinator lists BioDelivera as active.

Where is BioDelivera based?

BioDelivera lists San Francisco, CA, USA as its location on YC's directory.